XML 47 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment and Geographic Data
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment and Geographic Data SEGMENT AND GEOGRAPHIC DATA
Effective December 31, 2021 we segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine. This change realigns the Company's reportable business segments to its new internal reporting structure and how the Company manages its businesses as a result of the transition of responsibilities of our President and Chief Operating Officer, and the division of responsibilities between Group President, MedSurg and Neurotechnology, and Group President, Orthopaedics and Spine, in the fourth quarter of 2021. We have reflected these changes in all historical periods presented.
The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants.
Segment Results202120202019
MedSurg and Neurotechnology$9,538 $8,345 $8,475 
Orthopaedics and Spine7,570 6,006 6,409 
Net sales$17,108 $14,351 $14,884 
MedSurg and Neurotechnology$518 $496 $488 
Orthopaedics and Spine629 458 457 
Segment depreciation and amortization $1,147 $954 $945 
Corporate and Other125 122 99 
Total depreciation and amortization$1,272 $1,076 $1,044 
MedSurg and Neurotechnology$2,807 $2,414 $2,304 
Orthopaedics and Spine2,180 1,588 2,084 
Segment operating income$4,987 $4,002 $4,388 
Items not allocated to segments:
Corporate and Other$(605)$(503)$(480)
Acquisition and integration-related charges(585)(242)(275)
Amortization of intangible assets(619)(472)(464)
Restructuring-related and other charges(386)(458)(226)
Medical device regulations(107)(81)(62)
Recall-related matters(103)(17)(192)
Regulatory and legal matters2 (6)24 
Consolidated operating income$2,584 $2,223 $2,713 
Segment Assets and Capital Spending
Assets:202120202019
MedSurg and Neurotechnology$15,218 $15,250 $16,270 
Orthopaedics and Spine18,149 18,090 12,527 
Total segment assets$33,367 $33,340 $28,797 
Corporate and Other1,264 990 1,370 
Total assets$34,631 $34,330 $30,167 
Purchases of property, plant and equipment:
MedSurg and Neurotechnology$197 $192 $281 
Orthopaedics and Spine165 150 138 
Total segment purchases of property, plant and equipment$362 $342 $419 
Corporate and Other163 145 230 
Total purchases of property, plant and equipment$525 $487 $649 
We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, restructuring-related charges, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally property, plant and equipment and noncurrent assets.
The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based on the geographic area of the Stryker location where the sales to the customer originated.
Geographic Information
Net SalesNet Property, Plant and Equipment
20212020201920212020
United States$12,321 $10,455 $10,957 $1,717 $1,645 
Europe, Middle East, Africa2,299 1,818 1,888 941 938 
Asia Pacific1,973 1,630 1,617 76 91 
Other countries515 448 422 99 78 
Total$17,108 $14,351 $14,884 $2,833 $2,752